We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Europe’s largest privately held biotech company, Germany-based BioNTech, has raised $270 million to support its work in developing personalized immunotherapies for cancer, ahead of an expected eventual stock market flotation.